ArticleFrontiers in oncology2021

High-Dose-Rate Brachytherapy as Monotherapy for Low- and Intermediate-Risk Prostate Cancer. Oncological Outcomes After a Median 15-Year Follow-Up.

Manuel Behmueller et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.